DE60132799D1 - Peroxisom proliferator aktivierten rezeptor alpha agonisten - Google Patents

Peroxisom proliferator aktivierten rezeptor alpha agonisten

Info

Publication number
DE60132799D1
DE60132799D1 DE60132799T DE60132799T DE60132799D1 DE 60132799 D1 DE60132799 D1 DE 60132799D1 DE 60132799 T DE60132799 T DE 60132799T DE 60132799 T DE60132799 T DE 60132799T DE 60132799 D1 DE60132799 D1 DE 60132799D1
Authority
DE
Germany
Prior art keywords
activated receptor
receptor alpha
proliferator activated
alpha agonists
peroxisom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60132799T
Other languages
English (en)
Other versions
DE60132799T2 (de
Inventor
Nathan Bryan Mantlo
Cano Ivan Collado
Samuel James Dominianni
Garret Jay Etgen
Cristina Garcia-Paredes
Richard Duane Johnston
Michael Edward Letourneau
Michael John Martinelli
Daniel Ray Mayhugh
Ashraf Saeed
Richard Craig Thompson
Xiadong Wang
David Scott Coffey
Christopher Randall Schmid
Jeffrey Thomas Vicenzi
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60132799D1 publication Critical patent/DE60132799D1/de
Publication of DE60132799T2 publication Critical patent/DE60132799T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60132799T 2000-11-10 2001-11-09 Peroxisom proliferator aktivierten rezeptor alpha agonisten Expired - Fee Related DE60132799T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10
US247317P 2000-11-10
PCT/US2001/042928 WO2002038553A2 (en) 2000-11-10 2001-11-09 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists

Publications (2)

Publication Number Publication Date
DE60132799D1 true DE60132799D1 (de) 2008-03-27
DE60132799T2 DE60132799T2 (de) 2009-03-19

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132799T Expired - Fee Related DE60132799T2 (de) 2000-11-10 2001-11-09 Peroxisom proliferator aktivierten rezeptor alpha agonisten

Country Status (35)

Country Link
US (3) US7304062B2 (de)
EP (1) EP1335908B1 (de)
JP (1) JP4243101B2 (de)
KR (1) KR100839705B1 (de)
CN (1) CN1479728A (de)
AR (1) AR031305A1 (de)
AT (1) ATE386026T1 (de)
AU (3) AU2859202A (de)
BR (1) BR0114986A (de)
CA (1) CA2421154A1 (de)
CY (1) CY1107388T1 (de)
CZ (1) CZ20031283A3 (de)
DE (1) DE60132799T2 (de)
DK (1) DK1335908T3 (de)
EA (1) EA006920B1 (de)
EC (1) ECSP034595A (de)
ES (1) ES2300378T3 (de)
HK (1) HK1058790A1 (de)
HR (1) HRP20030365A2 (de)
HU (1) HUP0301655A2 (de)
IL (2) IL154840A0 (de)
MX (1) MXPA03004141A (de)
MY (1) MY157884A (de)
NO (1) NO20032059L (de)
NZ (1) NZ524569A (de)
PE (1) PE20020693A1 (de)
PL (1) PL362692A1 (de)
PT (1) PT1335908E (de)
SI (1) SI1335908T1 (de)
SK (1) SK5412003A3 (de)
SV (1) SV2003000727A (de)
TW (1) TW200716572A (de)
UA (1) UA82048C2 (de)
WO (1) WO2002038553A2 (de)
ZA (1) ZA200302517B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2006010545A1 (en) 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
DOP2006000018A (es) * 2005-01-28 2006-07-15 Lilly Co Eli Formulaciones y regimen de dosificación para moduladores alfa de ppar
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
EP1862464A4 (de) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk Neues cyclisches aminophenylalkansäurederivat
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
AU2008218841A1 (en) * 2007-02-23 2008-08-28 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
CN101657433A (zh) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
WO2010064633A1 (ja) 2008-12-01 2010-06-10 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
MX2015007433A (es) * 2012-12-20 2015-12-07 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
WO2015035059A1 (en) * 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
CN115398657A (zh) 2020-04-10 2022-11-25 松下知识产权经营株式会社 热电转换元件、热电转换组件、接合材料和热电转换元件的制造方法
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
EP1028111B1 (de) * 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amidderivate oder deren salze
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
IL154840A (en) 2009-09-22
DE60132799T2 (de) 2009-03-19
HK1058790A1 (en) 2004-06-04
KR20030048133A (ko) 2003-06-18
KR100839705B1 (ko) 2008-06-19
AR031305A1 (es) 2003-09-17
EA006920B1 (ru) 2006-04-28
CN1479728A (zh) 2004-03-03
SK5412003A3 (en) 2004-01-08
SV2003000727A (es) 2003-01-13
ATE386026T1 (de) 2008-03-15
AU2006202811A1 (en) 2006-07-20
PT1335908E (pt) 2008-05-08
WO2002038553A3 (en) 2003-05-01
JP4243101B2 (ja) 2009-03-25
EA200300558A1 (ru) 2004-02-26
NO20032059D0 (no) 2003-05-08
US7868225B2 (en) 2011-01-11
UA82048C2 (uk) 2008-03-11
EP1335908A2 (de) 2003-08-20
NO20032059L (no) 2003-06-24
JP2004513166A (ja) 2004-04-30
DK1335908T3 (da) 2008-06-02
CZ20031283A3 (cs) 2003-09-17
BR0114986A (pt) 2003-09-23
ECSP034595A (es) 2003-06-25
AU2002228592B2 (en) 2006-04-27
NZ524569A (en) 2006-05-26
ES2300378T3 (es) 2008-06-16
IL154840A0 (en) 2003-10-31
SI1335908T1 (sl) 2008-08-31
MY157884A (en) 2016-08-01
PL362692A1 (en) 2004-11-02
PE20020693A1 (es) 2002-08-05
CA2421154A1 (en) 2002-05-16
ZA200302517B (en) 2004-06-30
EP1335908B1 (de) 2008-02-13
US7304062B2 (en) 2007-12-04
US20040102500A1 (en) 2004-05-27
MXPA03004141A (es) 2003-08-19
WO2002038553A2 (en) 2002-05-16
CY1107388T1 (el) 2012-12-19
HRP20030365A2 (en) 2003-08-31
US20090062358A1 (en) 2009-03-05
TW200716572A (en) 2007-05-01
US20090044299A1 (en) 2009-02-12
AU2002228592B8 (en) 2006-08-24
HUP0301655A2 (hu) 2003-12-29
AU2859202A (en) 2002-05-21

Similar Documents

Publication Publication Date Title
DE60132799D1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
NO20025115D0 (no) Muskarin agonister
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DK1189916T3 (da) N-pyrazol A 2A-receptoragonister
DE50005580D1 (de) Puffervorrichtung
EE200300191A (et) Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
DE60138706D1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
NO20012450L (no) Holdesegment for svivelanordning
DE60108460D1 (de) Kopfträgermechanismus
NO20042737L (no) Peroksisomproliferatoraktiverte receptoragonister
DE60143985D1 (de) Os
DE60126075D1 (de) Auftragsvorrichtung
ID30056A (id) Agonis-agonis 5-htif
DE60137845D1 (de) Rauscharmes spektroskopisches ellipsometer
ATA20952000A (de) Haltevorrichtung
SE0003995D0 (sv) Receptoragonister och antagonister
SE0003996D0 (sv) Receptorantagonister
DK1259419T3 (da) Fortöjningsindretning
FI20002744A0 (fi) Kiinnitinlaite
SE0002228D0 (sv) New use
SE0002461D0 (sv) New use
SE0002196D0 (sv) New use
SE0001872D0 (sv) New use
SE0004363D0 (sv) New use
DK1330376T3 (da) Holdeindretning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee